Developer docs
API playgroundTry for free, no card

Search company profiles

Omega Funds

Full company profile

uuid00003ue

Namestring
Omega Funds
Legal namestring
Omega Fund Management, LLC
Websiteurl
omegafunds.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Omega Funds is a global life-sciences venture capital firm founded in 2003 (per the founder's biography) or 2004 (per the firm's Purpose page) by Otello Stampacchia and headquartered at 888 Boylston Street in Boston, Massachusetts, with a regional European office at Place du Molard 7, Geneva, Switzerland. The legal entity is Omega Fund Management, LLC, a Massachusetts-domiciled LLC. The firm operates a series of flagship investment funds — currently spanning Funds IV through VIII — and pursues a stage-agnostic investment model covering four explicit strategies: Company Creation, Primary Venture, Direct Secondaries, and Public Investments (PIPEs/IPOs). Geographic focus is concentrated in North America and Western Europe, with opportunistic global participation.

Across these strategies, Omega Funds invests in transformative life-sciences companies across therapeutic areas including oncology, immunology, rare diseases, and precision medicine, targeting exceptional founders, scientists and entrepreneurs. Since inception the firm has invested in more than 150 portfolio companies and supported 54 marketed products brought to patients, including Blincyto, Breyanzi, Kimmtrak, Imlygic, Heplisav-B, Lyxumia, Mavyret, Viekira Pak, Trilogy, Rezzayo, Rivfloza, Zoryve, Ibtrozi, Encelto, and Baxfendy. Major recent lead transactions include the $197M Alveus Therapeutics Series A, the $217M Third Arc Bio Series A, the $67M Spiro Medical Series A, the $112.5M Caldera Therapeutics launch financing, and the original $275M Nuvation Bio Series A. Realizations include the Bicara Therapeutics, Upstream Bio, Lexeo Therapeutics, Beta Bionics, Arcutis, Morphic, Prevail, Translate Bio and Trevi IPOs, and the CinCor (AstraZeneca), EyeBio (Merck), Imago BioSciences (Merck), SoniVie (Boston Scientific), Amunix (Sanofi), and Chord Therapeutics (Merck) acquisitions.

The firm employs approximately 22 named team members across five functional categories — Management, Investment Professionals, Advisors, Operations, and Administration — supplemented by portfolio board and observer seats across 20+ active investments. Revenue is generated via industry-standard fund management fees (typically 1.5–2.0% of committed capital annually) on the firm's active funds and carried interest (typically 20% above a hurdle) on successful realizations. Omega Funds maintains dedicated limited-partner portals (Altar Return for Funds VI/VII/VIII and Intralinks InvestorVision for Funds IV/V) and publishes thought-leadership content including the Omega Insights Series and Omega Position Papers.

Short descriptiontext

Omega Funds is a global life-sciences venture capital firm founded in 2004 that invests stage-agnostically — from company creation through IPO — across oncology, immunology, rare diseases, and precision medicine, serving entrepreneurs and limited partners from offices in Boston and Geneva.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, healthcare private equity, biotech investment funds, venture capital management, pharmaceutical investment firm
Industry1 code
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees (Fund VIII)
TypeSubscription Recurring
Description

In July 2025 Omega Funds closed an oversubscribed $647 million Fund VIII to invest in transformative life sciences companies. VC fund managers earn recurring management fees (industry-standard ~1.5–2% of committed capital annually during the investment period, declining during harvest) on committed and invested capital from limited partners.

wewillcure.com
2Carried Interest (Performance Fees)
TypeLicensing Royalties
Description

As a venture capital firm, Omega Funds is entitled to a carried interest (typically 20% of net fund profits above a hurdle) on successful realizations from portfolio companies. Exits and IPOs of portfolio companies (e.g., Bicara Therapeutics $362M IPO, Upstream Bio IPO, Lexeo Therapeutics IPO, Beta Bionics IPO, CinCor Pharma acquisition by AstraZeneca, Merck acquisitions of EyeBio and Imago BioSciences, SoniVie acquisition by Boston Scientific, Amunix acquisition by Sanofi, Checkmate acquisition by Regeneron, Chord Therapeutics acquisition by Merck, etc.) generate realized returns that drive carried-interest revenue.

omegafunds.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Omega Funds is a private venture capital firm that raises and manages life-sciences-focused investment funds (most recently Omega Fund VIII at $647 million, closed 2025) and deploys the capital across four strategies: company creation, primary venture, direct secondaries, and public investments (PIPEs/IPOs) in therapeutic areas such as oncology, immunology, rare diseases and precision medicine. The firm invests in early-, mid- and late-stage life-sciences companies primarily in North America and Western Europe, providing capital plus company-building expertise and a global co-investor network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 54 marketed products brought to patients since inception
+7 more records
Product overview1 text field

Omega Funds is a global life-sciences venture capital firm (founded 2004) whose offerings are a series of related flagship investment vehicles plus limited-partner services, rather than a software product. The unified offering is anchored by its family of funds — Omega Fund VIII (oversubscribed, $647M, 2025), Omega Fund VII ($650M, 2021), Omega Fund VI ($438M, 2019), and earlier vintages (Funds IV and V) — which sit on top of two operational LP portals: one hosted on AltaReturn for Funds VI, VII and VIII (omegafunds.altareturn.com) and one hosted on Intralinks for Funds IV and V (apps.intralinks.com/investorvision). Across these funds, Omega pursues four explicit investment strategies — Company Creation, Primary Venture, Direct Secondaries, and Public Investments — spanning early venture through public-market support for transformative life-sciences companies. The Omega Position Paper "AI in Drug Development and Discovery" (Oct 2025) and the Omega Insights Series webinars (covering GLP-1, AI in drug discovery, and US drug-pricing policy) sit alongside the funds as content/thought-leadership products that complement the core investing offering.

Product and service7 records
1Omega Fund VIII
CategoryVenture capital investment fund
Description

Oversubscribed $647 million flagship life-sciences investment fund closed in 2025 to invest in transformative life-sciences companies across stages and therapeutic areas; available to institutional limited partners.

2Omega Fund VII
CategoryVenture capital investment fund
Description

Seventh flagship life-sciences investment fund, an oversubscribed $650 million vehicle closed in December 2021 with emphasis on company creation; available to institutional limited partners.

3Omega Fund VI
CategoryVenture capital investment fund
Description

Sixth flagship life-sciences investment fund, a $438 million vehicle raised in December 2019 to invest across the future of medicine, supporting company creation, primary venture, direct secondaries, and public investments.

4Investor Portal - Omega Funds VI, VII & VIII
CategoryLimited-partner investor portal
Description

Web portal hosted on the AltaReturn platform providing limited partners of Omega Funds VI, VII, and VIII with fund information and reporting; governed by separate terms from the public site.

5Investor Portal - Omega Funds IV & V
CategoryLimited-partner investor portal
Description

Web portal hosted on the Intralinks platform providing limited partners of Omega Funds IV and V with fund information and reporting; governed by separate terms from the public site.

6Omega Fund V
CategoryVenture capital investment fund
Description

Fifth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.

7Omega Fund IV
CategoryVenture capital investment fund
Description

Fourth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1European Life Sciences Coalition (ELSC)
Strategic tierCore / Flagship Alliance - Shapes Omega Funds' Positioning On European Life-Sciences Capital Policy And Is One Of The Firm'S Highest-Profile Coalition RelationshipsTypeOthers
Description

Omega Funds is a co-founding member of the European Life Sciences Coalition (ELSC), launched in February 2026 in collaboration with Invest Europe. Other founding members include Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. The coalition collectively manages over €24 billion in life-sciences assets and aims to mobilize private and public capital to reverse Europe's share decline in global life-sciences VC (7% vs US 63% and China 14%) and stop the trend of European biotechs listing abroad (66 of 67 EU biotech IPOs in the past six years occurred outside the EU). ELSC does not seek subsidies but advocates for structural reform.

bioxconomy.com
Strategic tierCore / Coalition Founding PartnerTypeOthers
Description

Invest Europe collaborated with the European Life Sciences Coalition (ELSC) at its launch in February 2026 alongside Omega Funds, Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. ELSC aims to mobilize private and public funding to strengthen Europe's life-sciences investment environment.

Strategic tierCore / Coalition Co-Founding Partner And Frequent Co-InvestorTypeOthers
Description

Co-founding member of the European Life Sciences Coalition alongside Omega Funds. Sofinnova also co-led ARTBIO's $132M Series B with B Capital (August 2025), in which Omega Funds participated.

Strategic tierCore / Coalition Co-Founding Partner And Frequent Co-InvestorTypeOthers
Description

Co-founding member of the European Life Sciences Coalition alongside Omega Funds. Novo Holdings also participated in the second closing of Alveus Therapeutics' oversubscribed Series A (alongside Jeito Capital), bringing the total Series A round to $197 million in February 2026.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the world's largest healthcare-dedicated investment firms with multi-stage venture, royalty/credit, and public-equity strategies. Closest like-for-like to Omega across stage-agnostic life-sciences investing and is a frequent Omega co-investor (e.g., Alveus Series A syndicate).

TypeDirect peer
Description

Healthcare-focused crossover and venture investor with strong primary, secondary, and public-market capabilities. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor (e.g., Windward Bio).

TypeDirect peer
Description

European life-sciences specialist with primary venture and growth strategies. Direct co-investor in Omega-led rounds (e.g., Protego Biopharma Series B with Novartis Venture Fund) and co-founding ELSC member alongside Omega.

TypeDirect peer
Description

Paris- and Milan-based European life-sciences specialist across company creation and venture. Co-founding ELSC partner with Omega and a frequent co-investor (e.g., co-led ARTBIO's $132M Series B with B Capital).

TypeDirect peer
Description

Paris-based life-sciences and growth private equity firm. Co-led Omega's Alveus Therapeutics ($159.8M) and Spiro Medical ($67M) Series A rounds in January 2026, making it one of Omega's most frequent co-lead counterparties.

TypeDirect peer
Description

US healthcare-dedicated investment firm operating venture and public-equity strategies; closed a $1.3B life-sciences fund in 2025. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor.

TypeDirect peer
Description

Early-stage life-sciences venture firm focused on company creation in Cambridge, MA. Co-invested with Omega in Caldera Therapeutics ($75M Series A) and is part of the same Boston biotech VC ecosystem.

TypeDirect peer
Description

Denmark-based holding company of the Novo Nordisk Foundation with large-scale healthcare venture and growth strategies. Co-founding ELSC partner and a frequent Omega co-investor (e.g., second close of Alveus' $197M Series A).

TypeDirect peer
Description

Nordic-European life-sciences specialist investing across venture and growth stages. Co-founding ELSC partner alongside Omega and operates a comparable stage-agnostic, therapeutics-focused European model.

TypeBroad incumbent
Description

Generalist VC with a large, dedicated Bio + Health practice that co-leads and participates in life-sciences venture rounds (e.g., Third Arc Bio Series A extension led by a16z with Omega participation). Comparable as a healthcare venture investor but with a much broader overall fund footprint.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment165 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Omega Funds

Life Sciences Venture Capitalomegafunds.com

Omega Funds is a global life-sciences venture capital firm founded in 2004 that invests stage-agnostically — from company creation through IPO — across oncology, immunology, rare diseases, and precision medicine, serving entrepreneurs and limited partners from offices in Boston and Geneva.

What Omega Funds does

Omega Funds is a global life-sciences venture capital firm founded in 2003 (per the founder's biography) or 2004 (per the firm's Purpose page) by Otello Stampacchia and headquartered at 888 Boylston Street in Boston, Massachusetts, with a regional European office at Place du Molard 7, Geneva, Switzerland. The legal entity is Omega Fund Management, LLC, a Massachusetts-domiciled LLC. The firm operates a series of flagship investment funds — currently spanning Funds IV through VIII — and pursues a stage-agnostic investment model covering four explicit strategies: Company Creation, Primary Venture, Direct Secondaries, and Public Investments (PIPEs/IPOs). Geographic focus is concentrated in North America and Western Europe, with opportunistic global participation.

Across these strategies, Omega Funds invests in transformative life-sciences companies across therapeutic areas including oncology, immunology, rare diseases, and precision medicine, targeting exceptional founders, scientists and entrepreneurs. Since inception the firm has invested in more than 150 portfolio companies and supported 54 marketed products brought to patients, including Blincyto, Breyanzi, Kimmtrak, Imlygic, Heplisav-B, Lyxumia, Mavyret, Viekira Pak, Trilogy, Rezzayo, Rivfloza, Zoryve, Ibtrozi, Encelto, and Baxfendy. Major recent lead transactions include the $197M Alveus Therapeutics Series A, the $217M Third Arc Bio Series A, the $67M Spiro Medical Series A, the $112.5M Caldera Therapeutics launch financing, and the original $275M Nuvation Bio Series A. Realizations include the Bicara Therapeutics, Upstream Bio, Lexeo Therapeutics, Beta Bionics, Arcutis, Morphic, Prevail, Translate Bio and Trevi IPOs, and the CinCor (AstraZeneca), EyeBio (Merck), Imago BioSciences (Merck), SoniVie (Boston Scientific), Amunix (Sanofi), and Chord Therapeutics (Merck) acquisitions.

The firm employs approximately 22 named team members across five functional categories — Management, Investment Professionals, Advisors, Operations, and Administration — supplemented by portfolio board and observer seats across 20+ active investments. Revenue is generated via industry-standard fund management fees (typically 1.5–2.0% of committed capital annually) on the firm's active funds and carried interest (typically 20% above a hurdle) on successful realizations. Omega Funds maintains dedicated limited-partner portals (Altar Return for Funds VI/VII/VIII and Intralinks InvestorVision for Funds IV/V) and publishes thought-leadership content including the Omega Insights Series and Omega Position Papers.

Omega Funds firmographics

Firmographics
Name
Omega Funds
Legal name
Omega Fund Management, LLC
Website
https://omegafunds.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
Omega Funds is a global life-sciences venture capital firm founded in 2004 that invests stage-agnostically — from company creation through IPO — across oncology, immunology, rare diseases, and precision medicine, serving entrepreneurs and limited partners from offices in Boston and Geneva.
Ownership category
akta.pro rank

Omega Funds industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Life sciences venture capital
  • Healthcare private equity
  • Biotech investment funds
  • Venture capital management
  • Pharmaceutical investment firm

Where Omega Funds is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Omega Funds business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Fund Management Fees (Fund VIII): In July 2025 Omega Funds closed an oversubscribed $647 million Fund VIII to invest in transformative life sciences companies. VC fund managers earn recurring management fees (industry-standard ~1.5–2% of committed capital annually during the investment period, declining during harvest) on committed and invested capital from limited partners.
  2. Carried Interest (Performance Fees): As a venture capital firm, Omega Funds is entitled to a carried interest (typically 20% of net fund profits above a hurdle) on successful realizations from portfolio companies. Exits and IPOs of portfolio companies (e.g., Bicara Therapeutics $362M IPO, Upstream Bio IPO, Lexeo Therapeutics IPO, Beta Bionics IPO, CinCor Pharma acquisition by AstraZeneca, Merck acquisitions of EyeBio and Imago BioSciences, SoniVie acquisition by Boston Scientific, Amunix acquisition by Sanofi, Checkmate acquisition by Regeneron, Chord Therapeutics acquisition by Merck, etc.) generate realized returns that drive carried-interest revenue.

Go-to-market motion4 records

Marketing channels9 records

Omega Funds product offering

Product offering

Core offering

Omega Funds is a private venture capital firm that raises and manages life-sciences-focused investment funds (most recently Omega Fund VIII at $647 million, closed 2025) and deploys the capital across four strategies: company creation, primary venture, direct secondaries, and public investments (PIPEs/IPOs) in therapeutic areas such as oncology, immunology, rare diseases and precision medicine. The firm invests in early-, mid- and late-stage life-sciences companies primarily in North America and Western Europe, providing capital plus company-building expertise and a global co-investor network.

Product overview

Omega Funds is a global life-sciences venture capital firm (founded 2004) whose offerings are a series of related flagship investment vehicles plus limited-partner services, rather than a software product. The unified offering is anchored by its family of funds — Omega Fund VIII (oversubscribed, $647M, 2025), Omega Fund VII ($650M, 2021), Omega Fund VI ($438M, 2019), and earlier vintages (Funds IV and V) — which sit on top of two operational LP portals: one hosted on AltaReturn for Funds VI, VII and VIII (omegafunds.altareturn.com) and one hosted on Intralinks for Funds IV and V (apps.intralinks.com/investorvision). Across these funds, Omega pursues four explicit investment strategies — Company Creation, Primary Venture, Direct Secondaries, and Public Investments — spanning early venture through public-market support for transformative life-sciences companies. The Omega Position Paper "AI in Drug Development and Discovery" (Oct 2025) and the Omega Insights Series webinars (covering GLP-1, AI in drug discovery, and US drug-pricing policy) sit alongside the funds as content/thought-leadership products that complement the core investing offering.

Differentiator

Problem solved

Functional benefit

Products and services

  • Omega Fund VIII Oversubscribed $647 million flagship life-sciences investment fund closed in 2025 to invest in transformative life-sciences companies across stages and therapeutic areas; available to institutional limited partners.
  • Omega Fund VII Seventh flagship life-sciences investment fund, an oversubscribed $650 million vehicle closed in December 2021 with emphasis on company creation; available to institutional limited partners.
  • Omega Fund VI Sixth flagship life-sciences investment fund, a $438 million vehicle raised in December 2019 to invest across the future of medicine, supporting company creation, primary venture, direct secondaries, and public investments.
  • Investor Portal - Omega Funds VI, VII & VIII Web portal hosted on the AltaReturn platform providing limited partners of Omega Funds VI, VII, and VIII with fund information and reporting; governed by separate terms from the public site.
  • Investor Portal - Omega Funds IV & V Web portal hosted on the Intralinks platform providing limited partners of Omega Funds IV and V with fund information and reporting; governed by separate terms from the public site.
  • Omega Fund V Fifth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.
  • Omega Fund IV Fourth flagship life-sciences investment fund of Omega Funds; accessible to limited partners via the Intralinks investor portal.

Quantifiable outcome

  • 54 marketed products brought to patients since inception
  • +7 more outcomes

Companies that use Omega Funds

Customer profile

Segments5 records

Ideal customer profiles4 records

Omega Funds technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Omega Funds partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core / flagship alliance - shapes omega funds' positioning on european life-sciences capital policy and is one of the firm's highest-profile coalition relationships, core / coalition founding partner and core / coalition co-founding partner and frequent co-investor.

  • European Life Sciences Coalition (ELSC)core / flagship alliance - shapes omega funds' positioning on european life-sciences capital policy and is one of the firm's highest-profile coalition relationshipsOthersOmega Funds is a co-founding member of the European Life Sciences Coalition (ELSC), launched in February 2026 in collaboration with Invest Europe. Other founding members include Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. The coalition collectively manages over €24 billion in life-sciences assets and aims to mobilize private and public capital to reverse Europe's share decline in global life-sciences VC (7% vs US 63% and China 14%) and stop the trend of European biotechs listing abroad (66 of 67 EU biotech IPOs in the past six years occurred outside the EU). ELSC does not seek subsidies but advocates for structural reform.
  • Invest Europecore / coalition founding partnerOthersInvest Europe collaborated with the European Life Sciences Coalition (ELSC) at its launch in February 2026 alongside Omega Funds, Sofinnova Partners, Novo Holdings, Forbion, HealthCap, Cooley and Covington & Burling. ELSC aims to mobilize private and public funding to strengthen Europe's life-sciences investment environment.
  • Sofinnova Partnerscore / coalition co-founding partner and frequent co-investorOthersCo-founding member of the European Life Sciences Coalition alongside Omega Funds. Sofinnova also co-led ARTBIO's $132M Series B with B Capital (August 2025), in which Omega Funds participated.
  • Novo Holdingscore / coalition co-founding partner and frequent co-investorOthersCo-founding member of the European Life Sciences Coalition alongside Omega Funds. Novo Holdings also participated in the second closing of Alveus Therapeutics' oversubscribed Series A (alongside Jeito Capital), bringing the total Series A round to $197 million in February 2026.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Omega Funds competitors and assessment

Company assessment

Direct peers

  • OrbiMed: One of the world's largest healthcare-dedicated investment firms with multi-stage venture, royalty/credit, and public-equity strategies. Closest like-for-like to Omega across stage-agnostic life-sciences investing and is a frequent Omega co-investor (e.g., Alveus Series A syndicate).
  • RA Capital Management: Healthcare-focused crossover and venture investor with strong primary, secondary, and public-market capabilities. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor (e.g., Windward Bio).
  • Forbion: European life-sciences specialist with primary venture and growth strategies. Direct co-investor in Omega-led rounds (e.g., Protego Biopharma Series B with Novartis Venture Fund) and co-founding ELSC member alongside Omega.
  • Sofinnova Partners: Paris- and Milan-based European life-sciences specialist across company creation and venture. Co-founding ELSC partner with Omega and a frequent co-investor (e.g., co-led ARTBIO's $132M Series B with B Capital).
  • Andera Partners: Paris-based life-sciences and growth private equity firm. Co-led Omega's Alveus Therapeutics ($159.8M) and Spiro Medical ($67M) Series A rounds in January 2026, making it one of Omega's most frequent co-lead counterparties.
  • Frazier Life Sciences: US healthcare-dedicated investment firm operating venture and public-equity strategies; closed a $1.3B life-sciences fund in 2025. Directly comparable stage-agnostic life-sciences model and frequent Omega co-investor.
  • Atlas Venture: Early-stage life-sciences venture firm focused on company creation in Cambridge, MA. Co-invested with Omega in Caldera Therapeutics ($75M Series A) and is part of the same Boston biotech VC ecosystem.
  • Novo Holdings: Denmark-based holding company of the Novo Nordisk Foundation with large-scale healthcare venture and growth strategies. Co-founding ELSC partner and a frequent Omega co-investor (e.g., second close of Alveus' $197M Series A).
  • HealthCap: Nordic-European life-sciences specialist investing across venture and growth stages. Co-founding ELSC partner alongside Omega and operates a comparable stage-agnostic, therapeutics-focused European model.

Broad incumbents

  • Andreessen Horowitz (a16z) Bio + Health: Generalist VC with a large, dedicated Bio + Health practice that co-leads and participates in life-sciences venture rounds (e.g., Third Arc Bio Series A extension led by a16z with Omega participation). Comparable as a healthcare venture investor but with a much broader overall fund footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Omega Funds social profiles

Digital presence

Omega Funds financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Omega Funds leadership team

Management profile

Number of profiles

Profiles13 records

Omega Funds subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Omega Funds funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Omega Funds M&A and investment

M&A and investment

M&A

Investments165 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Omega Funds

What does Omega Funds do?

Omega Funds is a private venture capital firm that raises and manages life-sciences-focused investment funds (most recently Omega Fund VIII at $647 million, closed 2025) and deploys the capital across four strategies: company creation, primary venture, direct secondaries, and public investments (PIPEs/IPOs) in therapeutic areas such as oncology, immunology, rare diseases and precision medicine. The firm invests in early-, mid- and late-stage life-sciences companies primarily in North America and Western Europe, providing capital plus company-building expertise and a global co-investor network.

Is Omega Funds a public or private company?

Omega Funds is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Omega Funds founded?

Omega Funds was founded in 2004. It employs 11 to 50 people.

Where is Omega Funds based?

Omega Funds is headquartered in Boston, United States, in the North America region.

How does Omega Funds make money?

Two revenue lines are on record. Fund Management Fees (Fund VIII) is the primary driver. The others are carried Interest (Performance Fees).

Who are Omega Funds's main competitors?

Direct peers on record are OrbiMed, RA Capital Management, Forbion, Sofinnova Partners, Andera Partners, Frazier Life Sciences, Atlas Venture, Novo Holdings and HealthCap. Andreessen Horowitz (a16z) Bio + Health is listed as a broad incumbent.

Does Omega Funds have an API?

No public API is recorded for Omega Funds.

What industry is Omega Funds in?

Omega Funds's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magAnaconda Biomed Secures $56 Million in FinancingAnaconda Biomed closed a $56 million financing round led by Omega Funds and FOCO, with participation from Asabys, Ysios Capital, and CDTI. The funds will support product development and the ATHENA pivotal IDE study for its ANA Funnel Catheter. The company targets the large stroke intervention market, where nearly 270,000 mechanical thrombectomy procedures were performed in 2026.pharmaphorumWhich biotechs have raised new VC financing this week?Vaderis Therapeutics raised $152 million in second-round financing to fund its phase 3 trial of engasertib for hereditary haemorrhagic telangiectasia. Aureka Biotechnologies closed a $100 million Series B, Epicrispr raised $90 million, Infinimmune added $75 million, and Boulevard Bio emerged with $65 million.European BiotechnologySwiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3Vaderis Therapeutics raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia. The financing, led by Goldman Sachs Alternatives and TCGX, supports the first HHT-specific therapy, with positive proof-of-concept data. The company aims to secure regulatory approval and commercialization.FinSMEsVaderis Therapeutics Raises $152M in Series B FundingVaderis Therapeutics raised $152M in Series B funding led by Goldman Sachs Alternatives and TCGX. The company will use the funds for operations, regulatory submissions, and its Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia.PR NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioWorldVaderis grabs $152M series B for HHT phase IIIVaderis Therapeutics closed an oversubscribed $152 million series B to advance engasertib (VAD-044) for hereditary hemorrhagic telangiectasia. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors.Tech TimesHHT Patients Get First Phase 3 Drug Trial After 130 Years Without TreatmentVaderis Therapeutics closed a $152 million Series B and launched HEROIC, the first global Phase 3 trial for engasertib in hereditary hemorrhagic telangiectasia. The drug showed a 41% reduction in bleeding duration in a prior proof-of-concept study. The trial aims to secure the first FDA approval for HHT.NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioSpaceVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.PR NewswireEQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financingEQT Life Sciences invested $17.5 million in Vaderis Therapeutics' $152 million Series B financing, co-led with Goldman Sachs Alternatives and TCGX. The funds will support the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia, a rare vascular disease with no approved therapies. The trial follows positive proof-of-concept data published in The New England Journal of Medicine.